ImmunityBio shares target raised on Anktiva pricing strategy By Investing.com

Published on 29 Apr 2024 on Investing.com

On Monday, ImmunityBio Inc (NASDAQ:IBRX) saw its price target increased by Piper Sandler from $5.00...

Read the rest of the article

Start tracking your investments with Statfolio

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In t...

Insider Monkey · via Yahoo Finance 23 Nov 2024

EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX), a vertically integrated...

Benzinga · via AOL 25 Oct 2024

EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX), a vertically integrated...

Benzinga · via Yahoo Finance 23 Oct 2024

We recently compiled a list of the 10 Best Fast-Growing Penny Stocks to Buy Now. In this article,...

Insider Monkey · via Yahoo Finance 21 Sep 2024

ImmunityBio’s IBRX commercial portfolio comprises its only marketed drug, Anktiva (N-803, or noga...

Zacks · via Yahoo Finance 20 Jun 2024

Mullen Automotive, Inc. MULN shares are trading higher Monday after the company announced the Cal...

Benzinga 29 Apr 2024

Super Micro Computer, Inc. SMCI shares are trading higher Monday, and the stock is up more than 2...

Benzinga 29 Apr 2024

Approval clears way for distribution.

Los Angeles Business Journal 29 Apr 2024

On Monday, ImmunityBio Inc (NASDAQ:IBRX) saw its price target increased by Piper Sandler from $5....

Investing.com 29 Apr 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.40%

Investing.com 26 Apr 2024